Genetics of pheochromocytoma and paraganglioma
- 1 February 2002
- journal article
- multihormonal systems-disorders
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 9 (1) , 79-86
- https://doi.org/10.1097/00060793-200202000-00010
Abstract
During the past 10 years susceptibility genes have been identified for inherited cancer syndromes involving pheochromocytomas including multiple endocrine neoplasia type 2, caused by germline mutations in the RET proto-oncogene and von Hippel-Lindau disease, caused by germline mutations of the tumor suppressor gene VHL. More recently, the role of the mitochondrial complex II peptides in the tumorigenesis of paragangliomas has unfolded. The challenge for the future is to further clarify the normal functions of the genes involved in the tumorigenesis of pheochromocytomas and paragangliomas and the mechanisms by which their activation or inactivation leads to the tumorigenic phenotype. This review focuses on recent developments in the genetics of pheochromocytomas and paragangliomas and the significance of these genetic changes to understanding the disease phenotype, not only in familial but also in sporadic disease.Keywords
This publication has 73 references indexed in Scilit:
- 6-[ 18 F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of PheochromocytomaHypertension, 2001
- Novel mutations and the emergence of a common mutation in theSDHD gene causing familial paragangliomaAmerican Journal of Medical Genetics, 2001
- Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective studyActa Endocrinologica, 2001
- Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesisJournal of Medical Genetics, 2000
- Clinical Experience Over 48 Years With PheochromocytomaAnnals of Surgery, 1999
- Germline Dinucleotide Mutation in Codon 883 of the RETProto-Oncogene in Multiple Endocrine Neoplasia Type 2B Without Codon 918 MutationJournal of Clinical Endocrinology & Metabolism, 1997
- The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysisPublished by American Medical Association (AMA) ,1996
- Characterization of a multicomponent receptor for GDNFNature, 1996
- GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNFCell, 1996
- Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation ConsortiumJournal of Internal Medicine, 1995